Previous Article | Next Article 
Infection and Immunity, November 1998, p. 5175-5182, Vol. 66, No. 11
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Immunological Characterization of Asp f 2, a Major
Allergen from Aspergillus fumigatus Associated with Allergic
Bronchopulmonary Aspergillosis
Banani
Banerjee,1
Paul A.
Greenberger,2
Jordan N.
Fink,1 and
Viswanath
P.
Kurup1,*
Department of Medicine, Division of
Allergy-Immunology, The Medical College of Wisconsin, Milwaukee,
Wisconsin 53226, and Research Service, Veterans Affairs Medical Center,
Milwaukee, Wisconsin 53295,1 and
Division of Allergy/Immunology Northwestern University Medical
School, Chicago, Illinois 606112
Received 5 June 1998/Returned for modification 16 July
1998/Accepted 14 August 1998
 |
ABSTRACT |
The 37-kDa recombinant protein Asp f 2, encoding an allergen of
Aspergillus fumigatus, was expressed in a prokaryotic
expression system and immunologically evaluated for its functional and
structural properties. The open reading frame for a 310-amino-acid-long
protein was shown to encode a signal peptide of 31 amino acids. A
native 37-kDa culture filtrate protein and a 55-kDa mycelial
glycoprotein (gp55) exhibited complete N-terminal sequence homology to
Asp f 2. A GenBank search for homologous proteins revealed 60 and 44%
sequence homologies to the cytosolic protein ASPND1 from
Aspergillus nidulans and fibrinogen binding protein from
Candida albicans, respectively. The glycosylation sites and
cysteine molecules are conserved in all the three proteins. The
extracellular matrix protein laminin showed a dose-dependent
interaction with Asp f 2. This protein, expressed as a major
cell-associated protein within 24 h of in vitro fungal culture,
comprises 20 to 40% of total fungal protein. Furthermore, both native
and recombinant Asp f 2 exhibited specific immunoglobulin (IgE) binding
with allergic bronchopulmonary aspergillosis (ABPA) and cystic
fibrosis-ABPA patients, whereas A. fumigatus-sensitized
allergic asthma and normal control subjects failed to show IgE binding
with Asp f 2. These results indicate that Asp f 2 is a major allergen
of A. fumigatus exhibiting IgE antibody binding with sera
from patients with ABPA. The antigen should be explored further for its
potential role in the differential diagnosis of A. fumigatus-associated allergic diseases.
 |
INTRODUCTION |
One of the major
Aspergillus species responsible worldwide for fungal
respiratory disorders is the opportunistic pathogen Aspergillus
fumigatus. It is associated with a wide spectrum of diseases in
humans and animals such as hypersensitivity pneumonitis, allergic
asthma (AA), allergic bronchopulmonary aspergillosis (ABPA), and
aspergilloma as well as invasive aspergillosis in immunocompromised and
immunodeficient patients (5, 6, 29, 51). ABPA is the most
severe A. fumigatus-induced respiratory disease and is
usually found in atopic individuals (19-21). Although previously considered a rare disease, ABPA is currently reported to
occur in about 1% of A. fumigatus-sensitized asthmatics,
while in patients with cystic fibrosis (CF) the incidence varies from 10 to 35% (7, 21, 32, 40). The major diagnostic criteria for ABPA are a history of asthma, immediate wheal and flare,
immunoglobulin E (IgE) mast cell-mediated cutaneous reactivity to
A. fumigatus, elevated total serum IgE (usually >1,000
ng/ml), elevated serum A. fumigatus-specific IgE and IgG,
pulmonary infiltrates, and central bronchiectasis (CB) (19-21,
48). However, these diagnostic criteria are not always present at
the same time even in patients with classic ABPA. In addition, CB and
pulmonary infiltrates, the hallmarks of ABPA, also occur in CF patients
without ABPA. Therefore, the serological detection of A. fumigatus-specific antibodies in patients is considered to be of
diagnostic importance in the differential diagnosis of
Aspergillus-induced asthma from ABPA and indistinguishable
ABPA in CF patients.
The antigens and allergens of A. fumigatus comprise a
heterogeneous mixture of proteins, carbohydrates, and glycoproteins (8, 22). Although several A. fumigatus antigenic
components have been purified and characterized by various methods,
there is still a paucity of purified and characterized antigens for reliable immunodiagnosis of A. fumigatus-induced diseases
(2, 29-31, 33, 44, 45, 47). In a recent study, cytoplasmic A. fumigatus allergens were reported to be recognized
exclusively by serum IgE of ABPA patients, whereas secretory proteins
were recognized by IgE antibodies in A. fumigatus-sensitized
asthmatics as well as ABPA patients (13). Hence,
purification and characterization of various cell-associated and
metabolic A. fumigatus proteins may aid in the differential
diagnosis of A. fumigatus-induced diseases. With the advent
of DNA technologies and biotechnological procedures, cloning and
production of large amounts of pure A. fumigatus allergens
are now possible (1, 4, 26, 37). Recently, phage surface
display technologies for cloning cDNA have been used for isolation and
characterization of a number of major and minor A. fumigatus
allergens (13-16, 23).
Recently we have reported the partial nucleotide sequence of a cDNA
clone representing the C-terminal region of a major A. fumigatus allergen, Asp f 2 (4). Here we present the
complete nucleotide sequence of Asp f 2 and expression of the mature
recombinant protein. The expression kinetics and immunochemical
properties of both the native and recombinant allergen were studied.
The results indicate that Asp f 2 is a major allergen of A. fumigatus, recognizing specific IgE antibodies in ABPA patients.
 |
MATERIALS AND METHODS |
The construction of a cDNA library in the
ZAPII vector was
carried out as described previously (26). As the cDNA clone was found to be incomplete at the N-terminal region, a genomic library
of A. fumigatus carrying inserts of 9 to 22 kb in
Fix II
vector (Stratagene, La Jolla, Calif.) was screened by using a
[32P]dATP-labeled cDNA clone, and a positive plaque was
identified. The Asp f 2 gene was amplified by PCR using
left-arm
sequences as the sense primer 5'ATTTGATTACAATTTTGTCCCACTC 3';
the antisense primer 5'CTAAGTGCAATGAAGCTGTCCACC 3' was
designed from the C-terminal-end sequences of Asp f 2 and using
DNA
isolated from the amplified plaque as the template. Long-range PCR was
carried out with an XL PCR kit as specified by the manufacturer
(Perkin-Elmer, Foster City, Calif.). The resulting 3,000-bp product
carrying the complete Asp f 2 gene was then cloned in a TA vector by
using a PCR 2.1 cloning kit (Invitrogen, San Diego, Calif.) and
sequenced by the chain termination method (49).
Megaprimer PCR amplification of the Asp f 2 gene.
The Asp f
2 gene for overexpression was obtained by megaprimer PCR amplification.
A 618-bp PCR product was amplified from the partial cDNA clone of Asp f
2 by using sense primer 5'GTCGGTGCCTACGATGTCATC 3' and the
C-terminal 5'AGTGCAATGAAGCTGTCCACCTTC3' sequence of Asp f 2 as the antisense primer. This PCR product was used further as the
antisense primer along with the Asp f 2 N-terminal sequence 5'GACGCTGGCGCGGTGACCTCGT 3' as the sense primer for PCR
amplification of the complete Asp f 2 gene. The PCR reaction was
performed with 300 ng of megaprimer and 80 ng of sense primer; the
template was 20 ng of TA cloned Asp f 2 DNA obtained from genomic
library of A. fumigatus. The amplification conditions were
30 cycles of 30 s at 94°C and 11 min at 65°C. An amplified PCR
product of 804 bp was purified from the gel, subcloned into PCR 2.1 vector (Invitrogen), and sequenced by the dideoxy-chain termination
method (49).
Expression of Asp f 2 protein.
To express mature Asp f 2 in
Escherichia coli, the amplified PCR product with a
BamHI site at the N-terminal end and XhoI site at
the C-terminal end was cloned and expressed in pET 23b(+) vector as
previously described (4). Recombinant Asp f 1 (rAsp f 1) and
rAsp f 12 were expressed in the same way in the pET expression system.
Purification of Asp f 2.
rAsp f 2 was expressed in the pET
system along with a six-histidine tag at its C-terminal end; a
Ni2+-nitrilotriacetic acid agarose column (Qiagen, Santa
Clarita, Calif.) was used to purify the proteins. Other A. fumigatus antigens such as native Asp f 2 (nAsp f 2) and culture
filtrate antigens (AF102 and AF104) were obtained as described earlier
(29). The cytosolic fraction complex (CFC) from A. fumigatus and ASPND1 protein from a mycelial extract of
Aspergillus nidulans were gifts from F. Leal (University of
Salamanca, Salamanca, Spain).
Production of polyclonal antibodies.
Three purified A. fumigatus proteins, rAsp f 2 and two nAsp f 2 proteins isolated
from separate strains of A. fumigatus, were used to immunize
BALB/c mice. In brief, 50 µg of purified protein was emulsified in an
equal volume of complete Freund's adjuvant and injected
subcutaneously. Three consecutive injections were given at weekly
intervals with antigen mixed in incomplete Freund's adjuvant. The
animals were bled, and anti-Asp f 2 antibodies were measured by
enzyme-linked immunosorbent assay (ELISA). Animals were bled by cardiac
puncture, and the serum was stored at
70°C. The rabbit polyclonal
serum against the p40 component of A. fumigatus was obtained
from F. Leal. All animal studies were approved by the institutional
animal studies committee.
Human serum samples.
Serum samples from three groups of
patients were used: 10 patients with CF who also had the diagnostic
criteria of ABPA (CF/ABPA group), 10 patients with asthma and with ABPA
(ABPA group) and 10 patients with asthma with immediate wheal and flare
skin reactivity to A. fumigatus and without sufficient
features of ABPA (AA group). Sera from the CF/ABPA patients satisfying
the criteria for ABPA as reported previously were obtained from the
regional CF center at the Medical College of Wisconsin (39).
ABPA and AA patients were seen at the Division of Allergy-Immunology of
the Northwestern University Medical School or the Medical College of
Wisconsin. Serum samples from 10 control (healthy) subjects also were
selected. The human study committees of the Medical College of
Wisconsin and Northwestern University Medical School approved this
investigation.
Aspergillus mycelial extract and culture filtrate
antigen preparation.
Aspergillus conidia
(107/ml) were grown in Czapek-Dox-AOAC (1:1) liquid medium
at 37°C under continuous shaking to isolate mycelial antigens. The
cultures were harvested at 24 h, 48 h, 72 h, 96 h,
5 days, 7 days, 14 days, and 21 days, and the mycelia and culture
filtrates were collected separately. The mycelia were washed and
disrupted in a French press at a pressure of 16,000 lb/in2
and centrifuged. The supernatants were dialyzed against distilled water, and the retentate was freeze-dried (12). The culture filtrates were dialyzed and lyophilized in the same way as mycelial extracts. The protein concentrations of the extracts were determined by
BCA (bicinchoninic acid) assay (BCA kit; Pierce Chemicals, Rockford,
Ill.).
Kinetics of Asp f 2 production.
An ELISA was carried out to
measure Asp f 2 harvested at different time intervals from culture
filtrates and mycelial extracts. The amount of Asp f 2 in the
preparations was detected by treating antigen (1 µg/ml)-coated
microtiter plates with mouse anti-rAsp f 2 antibodies (1:500) for
3 h (27). The subsequent steps, including the addition
of biotinylated anti-mouse IgG, enzyme, and substrate, were as
described previously (27). Asp f 2 concentrations at different stages of A. fumigatus growth were calculated from
a standard curve plotted for concentration of Asp f 2 ranging from 10 to 500 ng/ml.
Antigen-specific ELISA.
The purified rAsp f 2 was evaluated
for IgE antibody binding with sera from the various subject groups by
ELISA as previously described (10).
Inhibition ELISA.
Monospecific mouse sera raised against
recombinant and native Asp f 2 were diluted 1:500 and incubated with
various concentrations of rAsp f 2 (1 ng to 10 µg) overnight at
4°C. The serum samples were centrifuged, and the supernatants were
transferred to the washed and blocked nAsp f 2-coated plates. Further
steps in the assay were carried out with reagents as described before
(3, 4). The dose-dependent inhibition of antibody titers was
determined from the ELISA (absorbance optical density [OD] values)
compared with uninhibited serum.
Asp f 2 production in A. fumigatus cultures.
Antigenic fractions from mycelia and culture filtrates collected at
various stages of growth (5 µg per sample) were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 12%
gel and transferred onto a nitrocellulose membrane by using a
trans-blot apparatus as described previously (4). After blocking and washing, the membranes were treated with anti-rAsp f 2 antibodies (1:250) and reactivity was analyzed by Western blotting
(4).
Western blotting of various Aspergillus antigens with
anti-Asp f 2 and anti-p40 antibodies.
The antigenic similarities
between Asp f 2, ASPND1 from A. nidulans, and other A. fumigatus antigenic components were analyzed by Western blotting
using mouse antisera against rAsp f 2 and rabbit antisera against p40
protein from the cytosolic fraction of A. fumigatus culture.
The culture filtrate proteins from strain AF102, the CFC of A. fumigatus (consisting mainly of proteins p90, p60, p40, and p37),
rAsp f 2, and protein ASPND1 purified from mycelial extracts of
A. nidulans were separated by SDS-PAGE (12% gel) at a
concentration of 5 µg sample per lane and transferred onto a
nitrocellulose membrane, and reactivities of the resolved proteins were
determined by Western blot assay as described previously (28,
29).
IgE binding of Asp f 2 and ASPND1.
An antigen-specific ELISA
was carried out to compare the IgE binding of ASPND1 to that of Asp f
2, using sera from three groups of subjects. Ten individual serum
samples from the ABPA, AA, and control groups were used, and the ELISA
was carried out as described above (3, 27).
Laminin-Asp f 2 interaction.
Wells of microtiter plates were
coated overnight with rAsp f 1, rAsp f 2, rAsp f 12, nAsp f 2, and
A. fumigatus culture filtrate antigens at 100 µg/ml and
incubated first with 10 µg of laminin (Boehringer Mannheim) per ml
for 3 h at room temperature and then with mouse antilaminin
antibody (Sigma, St. Louis, Mo.) at a 1:1,000 dilution for 1 h.
The subsequent incubations were with biotinylated goat anti-mouse IgG
(1:1,000) and streptavidin peroxidase (1:10,000) for 1 h each. The
color reaction was developed, and the intensity of the reaction was
measured as OD as described previously (3, 4).
The binding of Asp f 2 to laminin was evaluated by ELISA where the
wells of the microtiter plate were coated with Asp f 2 (4 µg/ml)
followed by addition of laminin (1 ng to 10 µg). In another set of
experiments, laminin (1 ng to 10 µg) was added directly to the wells.
Further steps include addition of mouse antilaminin antibody,
biotinylated goat anti-mouse IgG, streptavidin peroxidase, and
chromogen substrate as described earlier (3, 4). The
reactivities in the two plates were compared.
Statistical analysis.
The mean (± standard deviation
[SD]) OD values of antigen-antibody reactions by ELISA using serum
samples from the four groups of subjects were compared with those of
the control group by using Student's t test (two-tailed
independent samples) with the Statworks program (Cricket Software,
Inc., Philadelphia, Pa.). Values for ABPA, CF/ABPA, AA, and control
groups were compared, and P < 0.05 was taken as
significant.
Nucleotide sequence accession number.
The GenBank accession
no. for Asp f 2 is U56938.
 |
RESULTS |
Nucleotide and deduced amino acid sequences of Asp f
2.
We recently reported the expression of a truncated protein from
a cDNA clone of A. fumigatus having strong allergenic
activity (4). In the present study, in order to isolate the
complete Asp f 2 gene, this cDNA clone was labeled with
[32P]dATP and used as a probe to screen the A. fumigatus genomic library. Eleven positive plaques were identified
by screening 50,000 plaques. A PCR-amplified product of 939 bp was
detected in all plaque lysates, indicating the presence of the correct inserts. One of the 11 plaques was selected for further cloning and
sequencing. With isolated
DNA as the template, the
left-arm primer as the sense primer, and the C-terminal-end nucleotide sequences
from the cDNA clone as the antisense primer, a 3,000-bp PCR product was
obtained. The PCR product was cloned into PCR 2.1 vector, and the
plasmid DNA was sequenced. The complete nucleotide sequence of the Asp
f 2 gene is shown in Fig. 1. Comparison
of the cDNA and genomic sequences shows that the Asp f 2 gene consists of three exons encoding a 310-amino-acid-long protein interrupted by
two introns of 83 and 52 bp. Both introns have 5'GT and 3'AG dinucleotides at the intron-exon junctions involved in the splicing process, and four possible glycosylation sites are located at Asn 57, 87, 143, and 216 (Fig. 1, boldface). The deduced amino acid sequence of
this gene exhibits complete homology with the amino acid sequence of
the cDNA clone starting from Glu 65 to the C-terminal-end Thr 310. However, the N-terminal amino acid residues of the nAsp f 2 are located
within the open reading frame starting from Asp 43 (Fig. 1,
underlined). The N-terminal 20-amino-acid sequence of a previously
reported A. fumigatus glycoprotein (gp55) exhibits complete
homology to Asp f 2 from Ala 32 to Pro 51 (Fig. 1, italics). This
sequence is preceded by a 31-amino-acid-long probable signal peptide
with a stretch of hydrophobic amino acids.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 1.
Complete nucleotide sequence and the deduced amino acid
sequence of the Asp f 2 gene of A. fumigatus. The intron
sequences are represented in lowercase. The 20 N-terminal amino acids
of the purified native mycelial protein gp55 demonstrate sequence
homology from amino acid 32 onward, as represented in italics. The
A. fumigatus culture filtrate protein with N-terminal
sequence homology from Asp 43 onward are underlined; glycosylation
sites are in boldface.
|
|
Sequence homology of Asp f 2 with cell wall-associated
proteins.
A search of GenBank by using the BLAST program revealed
a high degree of sequence homology to ASPND1, a recently described protein from A. nidulans, as well as to cell wall-associated
proteins from Candida albicans (12). Figure
2 shows the sequence alignment of Asp f
2, ASPND1, and fibrinogen binding protein from C. albicans. Asp f 2 and ASPND1 exhibited 60% sequence
identity and 75% similarity, whereas Asp f 2 had about 44% identity
and 65% similarity with fibrinogen binding protein and a similar
degree of identity with pH-regulated antigen 1 (PRA1) from C. albicans (12, 50). The four possible glycosylation
sites and eight cysteine molecules present in Asp f 2 also are
conserved in ASPND1 and C. albican proteins.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 2.
Conserved sequences of ASPND1 from A. nidulans, a fibrinogen binding protein from C. albicans
(C. alb p), and Asp f 2. The cysteine molecules and
glycosylation sites are conserved in all the three proteins.
|
|
Recombinant and native Asp f 2 are similar in structural
conformation.
To evaluate the specificity of anti-rAsp f 2 antibodies, an ELISA inhibition was carried out with mouse antibodies
raised against rAsp f 2, nAsp f 2 (AF104), and nAsp f 2 (AF102). The antibodies against these three proteins showed binding to solid-phase coated nAsp f 2 (AF104). This binding was inhibited by increasing amounts of recombinant Asp f 2 (Fig. 3).
We were able to inhibit more than 80% binding of these antibodies to
solid-phase coated nAsp f 2. For anti-nAsp f 2 (AF104), 550 ng of rAsp
f 2 was required to obtain 50% inhibition, whereas anti-rAsp f 2 and
anti-nAsp f 2 (AF102) required about 75 ng of rAsp f 2 to exhibit 50%
inhibition of binding to solid-phase coated native protein.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Inhibition of IgG binding to solid-phase coated nAsp f
2. Polyclonal mouse sera raised against nAsp f 2 AF102 ( ), nAsp f 2 AF104 ( ), and rAsp f 2 ( ) were preincubated overnight with
different amounts of rAsp f 2 as indicated on the x axis.
Preincubated serum samples were transferred to nAsp f 2 (AF104)-coated
wells, and antibody binding was measured.
|
|
High expression of Asp f 2 in mycelial extract.
The time
kinetics of Asp f 2 production in A. fumigatus culture
(AF104) were analyzed by comparing Asp f 2 levels in culture filtrates
and mycelial extracts over 21 days of shake culture. Asp f 2 could be
detected in the mycelial growth within 24 h of culture. This
protein represented about 20% of total mycelial proteins at 96 h
and 40% by day 7. This increase was followed by a gradual decrease and
stabilization at 30% during weeks 2 and 3 of culture (Table
1). The culture filtrates collected at the same intervals of growth after harvesting of the mycelium demonstrated significantly less secreted Asp f 2. The amount of Asp f 2 varied from 1.6% at 24 h to 0.5% at the 3 weeks of culture. In
Western blot analysis using mouse sera against rAsp f 2, both mycelial
and culture filtrate preparations at various time intervals exhibited
IgG binding in the molecular mass range of 35 to 37 kDa. More than one
protein band in this narrow range exhibited distinct antibody binding
(Fig. 4). Although the intensity of the
antibody binding was different, the mycelial extract showed a very high
level of Asp f 2 even at 24 h, whereas the 24-h, 48-h, and 5-day
culture filtrates exhibited binding with anti-Asp f 2 in the molecular
mass range of 35 to 37 kDa. The reason for complete absence of
secretory Asp f 2 at 72 h, 96 h, and 7 days of culture was
not clear; it may be due to the involvement of different secretory
pathways and regulatory mechanisms at different stages of fungal growth
or due to the metabolic degradation of the protein. On the other hand,
the stationary culture filtrates collected at various intervals of time
exhibited a gradual increase in Asp f 2 production from day 2 onward,
reaching the highest concentration at 2 weeks (data not shown). The
variation in antigenic profiles of culture filtrates from stationary
and shake cultures of A. fumigatus could be due to the
complex nature of the fungal morphology and metabolic pathways. For the
culture filtrates, a number of proteins appeared to have weak antibody
binding with anti-Asp f 2 in the wide range of 18 to 100 kDa (Fig. 4B).

View larger version (90K):
[in this window]
[in a new window]
|
FIG. 4.
Time kinetics of expression of Asp f 2 in A. fumigatus mycelial extracts. Mycelial proteins (5 µg/ml) at
various intervals of growth were separated by SDS-PAGE on a 12% gel
and transferred onto nitrocellulose membranes. Separated proteins were
evaluated for antibody binding by using polyclonal mouse sera against
rAsp f 2. Lane 1, molecular weight markers. Different time interval
cultures: lane 2, 24 h; lane 3, 48 h; lane 4, 72 h; lane
5, 96 h; lane 6, 5 days; lane 7, 7 days; lane 8, 14 days; lane 9, 21 days. (B) Time kinetics of expression of Asp f 2 in A. fumigatus culture filtrates. The culture filtrate proteins (5 µg/ml) were separated by SDS-PAGE on a 12% gel and transferred onto
nitrocellulose membranes. Separated proteins in lanes 2 to 9 are
culture filtrates at the same time intervals as for mycelial extracts
(A) and were evaluated for antibody binding by using polyclonal mouse
sera against rAsp f 2.
|
|
ASPND1 and Asp f 2 share common epitopes.
ASPND1, the protein
present in the water-soluble extract from A. nidulans,
exhibited significant sequence homology with Asp f 2. To ascertain the
presence of common epitopes in these proteins, antibody binding of
ASPND1 was evaluated by using polyclonal sera against rAsp f 2 and the
p40 component of CFC isolated from A. fumigatus culture. In
Western blots, rAsp f 2 and ASPND1 exhibited strong IgG binding with
sera against rAsp f 2 (Fig. 5, lanes d and e, respectively). Similarly, anti-p40 antibody exhibited strong IgG
binding with rAsp f 2 as well as ASPND1 (Fig. 5, lanes h and i,
respectively). However, ASPND1 when treated with anti-p40
antibodies demonstrated two additional IgG binding proteins at lower
molecular masses. At the same time, the CFC component of A. fumigatus (composed of p90, p60, p40, and p37 antigens) showed
similar antibody binding with anti-rAsp f 2 and anti-p40 antibodies,
with a doublet type of reaction at 35 to 40 kDa (Fig. 5, lanes c and
g). Crude A. fumigatus culture filtrate (AF102) showed
multiple anti-Asp f 2 as well as anti-p40 antibody binding proteins in
the molecular mass range of 18 to 70 kDa (Fig. 5, lanes b and f). These
results strongly suggest the presence of common antigenic epitopes in Asp f 2, ASPND1, and p40 A. fumigatus antigen. Purified
ASPND1 and Asp f 2 were evaluated by using an indirect ELISA for
specific IgE antibody binding in sera from ABPA (n = 10), AA (n = 10), and control (n = 10)
groups (Fig. 6). In ELISAs, the mean IgE absorbance value (OD at 490 nm [OD490]) for ASPND1 with
sera from ABPA patients was 0.25, compared to 0.05 for controls
(P < 0.001). However, the mean IgE absorbance value
for Asp f 2 in sera from ABPA patients was almost threefold higher
(OD490 of 0.708) than that with ASPND1 (OD490
of 0.248).

View larger version (96K):
[in this window]
[in a new window]
|
FIG. 5.
Western blot analysis of various Aspergillus
proteins, using mouse polyclonal sera against rAsp f 2 and rabbit sera
against the p40 cytosolic component of A. fumigatus. Lanes:
a, molecular weight markers; b to e, treated with anti-rAsp f 2 sera; f
to i, treated with anti-p40 sera; b and f, A. fumigatus
culture filtrate antigens (AF102); c and g, CFC fraction from A. fumigatus; d and h, rAsp f 2; e and i, ASPND1 from A. nidulans.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 6.
IgE binding of purified rAsp f 2 and ASPND1, using 10 serum samples from each of the indicated groups. Solid bars, ELISA
absorbance values at 490 nm for rAsp f 2; shaded bars, absorbance
values for ASPND1.
|
|
Specific binding of Asp f 2 to extracellular matrix protein
laminin.
Both recombinant and native Asp f 2 demonstrated high
binding affinity to laminin in a direct solid-phase ELISA. Laminin
binding of Asp f 2 was more than twofold higher than that with rAsp f 1 and rAsp f 12. However, native Asp f 2 exhibited higher affinity than
rAsp f 2 (Fig. 7A). For dose-dependent
binding of laminin to Asp f 2 in wells coated with a constant
concentration of Asp f 2, gradual increases in laminin concentration
resulted in increased binding with antilaminin antibodies (Fig. 7B),
indicating the specific interaction between laminin and Asp f 2. On the
other hand, high antilaminin antibody binding was observed in wells directly coated with 100 ng of laminin or more. With 1 µg of laminin, direct laminin-antilaminin interaction demonstrated
fourfold-higher ELISA absorbance (OD490 of 1.365)
than with Asp f 2-coated plates (OD490 of 0.295).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 7.
(A) Specific binding of laminin to Asp f 2. rAsp f 1, rAsp f 12, rAsp f 2, nAsp f 2, and crude A. fumigatus
culture filtrates (100 µg/well) were incubated with 10 µg of
laminin per ml. The subsequent incubation was with a 1:1,000 dilution
of mouse antilaminin antibody. The ELISA IgG absorbance was measured at
490 nm (for details, see Materials and Methods). (B) Dose-dependent
binding of laminin (1 ng to 10 µg) to solid-phase coated Asp f 2. Open bars, IgG absorbance of laminin-antilaminin interaction on Asp f
2-coated wells; closed bars, absorbance values for direct
laminin-antilaminin binding on laminin-coated wells.
|
|
Specific IgE binding of Asp f 2 in ABPA sera.
The biologically
active rAsp f 2, nAsp f 2, and crude culture filtrate AF104 were
evaluated for IgE antibody with 10 serum samples from each of the
CF/ABPA, ABPA, and AA groups of patients along with 10 healthy controls
(Fig. 8). Serum IgE antibody against all
of the antigens was elevated in CF/ABPA and ABPA patients in comparison
with AA patients and controls. The mean IgE absorbance in CF/ABPA
samples for both native and recombinant Asp f 2 was higher than in ABPA
samples. The difference between rAsp f 2-specific IgE in CF/ABPA (mean
0.606, SD ± 0.438) and control (mean 0.048, SD ± 0.042)
groups was statistically significant (P < 0.01). A significant difference was observed also for rAsp f 2-specific IgE
antibody in ABPA (mean 0.408, SD ± 0.380) and control groups (P < 0.01).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 8.
IgE binding of nAsp f 2, rAsp f 2, and A. fumigatus culture filtrate (AF104) with 10 serum samples from each
of the indicated groups.
|
|
 |
DISCUSSION |
Recently we reported the nucleotide sequence of a cDNA clone from
A. fumigatus representing the C-terminal region of Asp f 2 (4). The recombinant protein expressed in E. coli
without the N-terminal amino acid residues also exhibited distinct IgE binding with sera from ABPA patients and appeared to be a part of a
major allergen from A. fumigatus. These results prompted us
to isolate and characterize the gene carrying the complete nucleotide
sequence for Asp f 2 and also to clone and overproduce the recombinant
allergen.
The Asp f 2 sequence encodes a protein with a predicted molecular size
of 29 kDa. However, on SDS-PAGE analysis, this protein exhibited a band
at 37 kDa. Although the reasons for such differences are not clear,
they could be attributed to the amino acids at the C-terminal of the
protein. The involvement of C-terminal amino acids in slow migration of
Asp f 2 in SDS-PAGE is evident from the differences in the molecular
sizes of two recombinant polypeptides from Asp f 2, representing 200 amino acids from either the N- or C-terminal region of Asp f 2 (data
not shown). The polypeptide encoding the C-terminal A. fumigatus region migrated during SDS-PAGE to a position about 5 to
6 kDa greater than its predicted size. Similar differences between the
predicted molecular size of the native protein and the apparent size on
SDS-PAGE have been reported for serine proteases from A. fumigatus, mycelial antigen from A. nidulans, and cell
wall antigen from C. albicans (12, 24, 25, 36, 46,
50). For a Ca2+-dependent serine protease from
Saccharomyces cerevisiae, the deletion experiments precisely
demonstrated that the high negative change of the C-terminal region of
the protein is responsible for its slow migration in gel
(18).
Comparison of amino acid sequences of the product of the entire Asp f 2 gene with the N-terminal amino acid sequences of other purified
proteins exhibited complete homology with a recently purified and
characterized 37-kDa concanavalin A-nonbinding protein from an A. fumigatus AF104 culture filtrate and with another previously reported glycoprotein, gp55, characterized after isolation from a
water-soluble extract from mycelium of strain NHL5759 (3, 52). Both native proteins demonstrated complete N-terminal
sequence homology to the A. fumigatus gene characterized in
this study, starting from different N-terminal regions on the same
gene. This result indicates that the posttranslational modifications
such as phosphorylation, glycosylation, and enzymatic cleavages may be
responsible for the differences in the molecular weight of the same
core protein under different culture conditions and in different
strains of A. fumigatus. The 37-kDa culture filtrate protein
as well as deglycosylated gp55 showed high IgE binding, indicating that
the core protein without glycosylation in both molecules is involved in
IgE binding. Another 58-kDa glycoprotein antigen exhibiting high IgG
binding with sera from patients with aspergillosis appeared to be
different from Asp f 2 and gp55, as the antibody binding of this
protein was totally destroyed by treatment with sodium metaperiodate
and partially destroyed by protease treatment (17, 52).
As the correct three-dimensional structure of the allergen is essential
for IgE antibody binding, the Asp f 2 allergen overproduced in the
prokaryotic expression system is functionally comparable with its
native counterpart. In an ELISA inhibition study, mouse antisera
against native Asp f 2 preincubated with rAsp f 2 exhibited more than
80% inhibition in binding to solid-phase coated native protein,
indicating conformational similarities between these two proteins.
We have evaluated further the IgE antibody binding of recombinant and
native Asp f 2 as well as crude culture filtrate in four groups of
subjects. None of the AA patients, all of whom showed immediate
cutaneous reactivity to A. fumigatus, exhibited IgE binding
with Asp f 2 proteins, whereas all patients from the ABPA and CF/ABPA
groups showed IgE binding. In a recent study, the polypeptide
representing truncated Asp f 2 demonstrated distinct IgE antibody
binding with ABPA-CB patients, whereas IgE antibodies in ABPA-S
(seropositive for ABPA without CB) patients failed to show significant
binding to this protein (4). These observations indicated
the possible involvement of Asp f 2 in the acute phase of the disease
and bronchial wall injury in patients. The typical immune response of
Asp f 2 in ABPA-CB patients emphasized its use in differential
diagnosis of ABPA and other A. fumigatus-sensitized patients
as well as ABPA-S and ABPA-CB patients. Two recently reported
recombinant A. fumigatus allergens, rAsp f 4, and rAsp f 6, also demonstrated distinct IgE binding with ABPA patient sera, and
serodiagnosis with these two allergens together showed 100%
specificity and greater than 90% sensitivity (13, 15, 23,
34). In the present study, we found 100% specificity in CF/ABPA
patients and 90% in ABPA patients, while none of the controls showed
significant levels of Asp f 2-specific IgE. The other recombinant A. fumigatus allergens also demonstrated distinct IgE
binding in ABPA patients. However, they also reacted with IgE
antibodies of A. fumigatus-sensitized non-ABPA patients, and
this overlap in IgE binding lowers the specificity when these antigens
are used together (13, 37, 38).
The levels of high IgE antibodies against Asp f 2 in CF/ABPA patients
indicates the allergen's usefulness in the diagnosis of patients with
CF complicated by ABPA. In a recent study, intracellular rather than
secretory A. fumigatus proteins were reported to show distinct IgE antibody binding in CF patients with ABPA but not in CF
patients without ABPA (13, 41). Colonization of the fungus
in the bronchi and the release of intracellular proteins may be
responsible for sensitizing ABPA patients against nonsecretory fungal
proteins, whereas the nonavailability of intracellular A. fumigatus protein has been attributed to the lack of specific IgE
response against these allergens in A. fumigatus-sensitized allergic asthmatics.
Asp f 2, with its extensive sequence homology to fibrinogen binding
protein of C. albicans as well as its specific binding to
laminin, appears to be involved in fungal adherence to the extracellular matrix (9, 42, 43). Laminin and fibrinogen are
the major structural proteins of the basement membrane and are mainly
involved in mediating adherence of conidia to the extracellular matrix.
To our knowledge, this is the first A. fumigatus allergen reported to show distinct binding to major extracellular matrix proteins. Thus, one of the initial steps in host colonization may be
the recognition in patients of basement membrane laminin by Asp f 2. Recently, a 72-kDa cell wall surface component of A. fumigatus with receptors for laminin was reported (53).
The recently reported C. albicans antigen PRA1 demonstrated
pH-sensitive expression, with maximum expression at neutral pH and no
expression below pH 6.0 (50). Although Asp f 2 exhibited
high sequence homology and conserved glycosylation sites with PRA1, the
mycelial expression of Asp f 2 appears to be unaffected by the pH of
the medium. In shake culture, however, the secretion of Asp f 2 into the medium gradually decreases as the pH changes from neutral to
acidic. We cannot explain the high expression of Asp f 2 only at day 5 when the culture is acidic (Fig. 4B), with continuous decreases in
concentration in late cultures. The involvement of PRA1 in
temperature-dependent hypha formation suggests a possible role of this
protein family in fungal morphogenesis.
The extensive sequence homology between Asp f 2 and the mycelial
protein ASPND1 from A. nidulans as well as the presence of conserved glycosylation sites and cysteine molecules in these proteins
raises the possibilities of common antigenic and allergenic epitopes in
the two proteins (11, 12). Indeed, ASPND1 strongly reacted
with polyclonal anti-rAsp f 2 antibodies and also exhibited specific
IgE binding with sera from patients with ABPA, indicating the presence
of common B-cell epitopes in these two proteins. However, the threefold
less IgE binding with ASPND1 than with Asp f 2 may be due to the
differences in posttranslational modification and three-dimensional
structure of these two proteins. The peptide mapping studies of various
cytosolic A. fumigatus components demonstrated that p60,
p40, and p37 cytosolic proteins are the differentially modified forms
of a common peptide core (12). The antisera against the p40
component used in this study reacted strongly with rAsp f 2 as well as
ASPND1, indicating the presence of common core protein in all of these
antigens.
To obtain well-characterized and reproducible allergen preparations, it
is essential to identify the A. fumigatus proteins which are
produced by most of the strains and exhibit specific binding with
patient sera. Antisera raised against the recombinant allergens
expressed both in prokaryotic and eukaryotic systems should be used to
screen mycelial and culture filtrate preparations from various strains
of A. fumigatus as well as proteins from other
Aspergillus species in order to identify the commonly
expressed allergens. These allergens can be used for routine diagnosis
and analyzed for their involvement in the immunopathogenesis of
A. fumigatus-induced respiratory diseases.
In conclusion, the recombinant and native forms of the allergen Asp f 2 evaluated in this study are immunologically comparable, and the
distinct IgE binding ability of this major allergen with sera from ABPA
patients, particularly those with CB, may be of value for specific
diagnosis. Further analysis of this protein in fungal colonization
studies may shed new light in the role of A. fumigatus
allergens in the immunopathogenesis of ABPA.
 |
ACKNOWLEDGMENTS |
This investigation was supported in part by NIH grants AI 42349, the U.S. Veterans Affairs Medical Research Service, and an Ernest S. Bazley grant to Northwestern Memorial Hospital and Northwestern University.
We thank F. Leal for providing us the ASPND1 and CFC proteins and the
rabbit anti-p40 serum. We also gratefully acknowledge the technical
assistance of Nancy Elms, Laura Castillo, and Kevin Thompson and the
editorial assistance of Donna Schrubbe.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: VA Medical
Center, Research Service 151-I, 5000 West National Ave., Milwaukee, WI
53295. Phone: (414) 384-2000, ext. 1510. Fax: (414) 382-5374. E-mail: vkurup{at}post.its.mcw.edu.
Editor:
T. R. Kozel
 |
REFERENCES |
| 1.
|
Arruda, L. K.,
B. J. Mann, and M. D. Chapman.
1992.
Selective expression of a major allergen and cytotoxin, Asp f I, in Aspergillus fumigatus. Implications for the immunopathogenesis of Aspergillus-related diseases.
J. Immunol.
149:3354-3359[Abstract].
|
| 2.
|
Arruda, L. K.,
T. A. Platts-Mills,
J. W. Fox, and M. D. Chapman.
1990.
Aspergillus fumigatus allergen I, a major IgE binding protein, is a member of the mitogillin family of cytotoxins.
J. Exp. Med.
172:1529-1532[Abstract/Free Full Text].
|
| 3.
|
Banerjee, B.,
V. P. Kurup,
P. A. Greenberger,
D. R. Hoffman,
D. S. Nair, and J. N. Fink.
1997.
Purification of a major allergen, Asp f 2 binding to IgE in allergic bronchopulmonary aspergillosis, from culture filtrate of Aspergillus fumigatus.
J. Allergy Clin. Immunol.
99:821-827[Medline].
|
| 4.
|
Banerjee, B.,
V. P. Kurup,
S. Phadnis,
P. A. Greenberger, and J. N. Fink.
1996.
Molecular cloning and expression of a recombinant Aspergillus fumigatus protein AspfII with significant immunoglobulin E reactivity in allergic bronchopulmonary aspergillosis.
J. Lab. Clin. Med.
127:253-262[Medline].
|
| 5.
|
Bardana, E. J., Jr.
1981.
The clinical spectrum of aspergillosis. Part 1. Epidemiology, pathogenicity, infection in animals and immunology of aspergillosis.
Crit. Rev. Clin. Lab. Sci.
13:21-83[Medline].
|
| 6.
|
Bardana, E. J., Jr.
1981.
The clinical spectrum of aspergillosis. Part 2. Classification and description of saphorophytic, allergic and invasive variants of human disease.
Crit. Rev. Clin. Lab. Sci.
13:85-159[Medline].
|
| 7.
|
Basich, J. E.,
T. S. Graves,
M. N. Baz,
G. Scanlon,
R. G. Hoffman,
R. Patterson, and J. N. Fink.
1981.
Allergic bronchopulmonary aspergillosis in corticosteroid dependent asthmatics.
J. Allergy Clin. Immunol.
68:98-102[Medline].
|
| 8.
|
Bernstein, J. A.,
C. R. Zeiss,
P. A. Greenberger,
R. Patterson,
J. F. Marhoul, and L. L. Smith.
1990.
Immunoblot analysis of sera from patients with allergic bronchopulmonary aspergillosis: correlation with disease activity.
J. Allergy Clin. Immunol.
86:532-539[Medline].
|
| 9.
|
Bouchara, J. P.,
G. Tronchin,
G. Larcher, and D. Chabasse.
1995.
The search for virulence determinants in Aspergillus fumigatus.
Trends Microbiol.
8:327-330.
|
| 10.
|
Brummund, W.,
A. Resnick,
J. N. Fink, and V. P. Kurup.
1987.
Aspergillus fumigatus-specific antibodies in allergic bronchopulmonary aspergillosis and aspergilloma: evidence for a polyclonal antibody response.
J. Clin. Microbiol.
25:5-9[Abstract/Free Full Text].
|
| 11.
|
Calera, J. A.,
R. Lopez-Medrano,
M. C. Ovejero,
P. Puente, and F. Leal.
1994.
Variability of Aspergillus nidulans antigens with media and time and temperature of growth.
Infect. Immun.
62:2322-2333[Abstract/Free Full Text].
|
| 12.
|
Calera, J. A.,
M. C. Ovejero,
R. Lopez-Medrano,
M. Segurado,
P. Puente, and F. Leal.
1997.
Characterization of the Aspergillus nidulans aspnd1 gene demonstrates that the ASPND1 antigen, which it encodes, and several Aspergillus fumigatus immunodominant antigens belongs to the same family.
Infect. Immun.
65:1335-1344[Abstract].
|
| 13.
|
Crameri, R.
1998.
Recombinant Aspergillus fumigatus allergens: from the nucleotide sequences to clinical applications.
Int. Arch. Allergy Immunol.
115:99-114[Medline].
|
| 14.
|
Crameri, R., and K. Blaser.
1996.
Cloning Aspergillus fumigatus allergens by the pJuFo filamentous phage display system.
Int. Arch. Allergy Immunol.
110:41-45[Medline].
|
| 15.
|
Crameri, R.,
A. Faith,
S. Hemmann,
R. Jaussi,
C. Ismail,
G. Menz, and K. Blaser.
1996.
Humoral and cell-mediated autoimmunity in allergy to Aspergillus fumigatus.
J. Exp. Med.
184:265-270[Abstract/Free Full Text].
|
| 16.
|
Crameri, R.,
R. Jaussi,
G. Menz, and K. Blaser.
1994.
Display of expression products of cDNA libraries on phage surfaces. A versatile screening system for selective isolation of genes by specific gene-product/ligand interaction.
Eur. J. Biochem.
226:53-58[Medline].
|
| 17.
|
Fratamico, P. M., and H. R. Buckley.
1991.
Identification and characterization of an immunodominant 58-kilodalton antigen of Aspergillus fumigatus recognized by sera of patients with invasive aspergillosis.
Infect. Immun.
59:309-315[Abstract/Free Full Text].
|
| 18.
|
Fuller, R. S.,
A. Brake, and J. Thorner.
1989.
Yeast prohormone processing enzyme (KEX2 gene product) is a Ca2+ dependent serine protease.
Proc. Natl. Acad. Sci. USA
86:1434-1438[Abstract/Free Full Text].
|
| 19.
|
Greenberger, P. A.
1988.
Allergic bronchopulmonary aspergillosis and fungoses.
Clin. Chest Med.
9:599-608[Medline].
|
| 20.
|
Greenberger, P. A., and R. Patterson.
1986.
Diagnosis and management of allergic bronchopulmonary aspergillosis.
Ann. Allergy
56:444-448[Medline].
|
| 21.
|
Greenberger, P. A., and R. Patterson.
1988.
Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma.
J. Allergy Clin. Immunol.
81:646-650[Medline].
|
| 22.
|
Hearn, V. M., and J. H. Sietsma.
1994.
Chemical and immunological analysis of the Aspergillus fumigatus cell wall.
Microbiology
140:789-795[Abstract/Free Full Text].
|
| 23.
|
Hemmann, S.,
K. Blaser, and R. Crameri.
1997.
Allergens of Aspergillus fumigatus and Candida boidinii share IgE-binding epitopes.
Am. J. Respir. Crit. Care Med.
156:1956-1962[Abstract/Free Full Text].
|
| 24.
|
Jaton-Ogay, K.,
M. Suter,
R. Crameri,
R. Falchetto,
A. Faith, and M. Monod.
1992.
Nucleotide sequence of a genomic and a cDNA clone encoding an extracellular alkaline protease of Aspergillus fumigatus.
FEMS Microbiol. Lett.
71:163-168[Medline].
|
| 25.
|
Kolattukudy, P. E.,
J. D. Lee,
L. M. Rogers,
P. Zimmerman,
S. Ceselski,
B. Fox,
B. Stein, and E. A. Copelan.
1993.
Evidence for possible involvement of an elastolytic serine protease in aspergillosis.
Infect. Immun.
61:2357-2368[Abstract/Free Full Text].
|
| 26.
|
Kumar, A.,
L. V. Reddy,
A. Sochanik, and V. P. Kurup.
1993.
Isolation and characterization of a recombinant heat shock protein of A. fumigatus.
J. Allergy Clin. Immunol.
91:1024-1030[Medline].
|
| 27.
|
Kurup, V. P.
1986.
Enzyme-linked immunosorbent assay in the detection of specific antibodies against Aspergillus in patients' sera.
Zentralbl. Bakteriol. Mikrobiol. Hyg. Reiche A
261:509-516.
|
| 28.
|
Kurup, V. P.,
P. A. Greenberger, and J. N. Fink.
1989.
Antibody response to low-molecular-weight antigens of Aspergillus fumigatus in allergic bronchopulmonary aspergillosis.
J. Clin. Microbiol.
27:1312-1316[Abstract/Free Full Text].
|
| 29.
|
Kurup, V. P., and A. Kumar.
1991.
Immunodiagnosis of aspergillosis.
Clin. Microbiol. Rev.
4:439-456[Abstract/Free Full Text].
|
| 30.
|
Kurup, V. P.,
A. Resnick,
G. H. Scribner,
J. H. Kalbfleisch, and J. N. Fink.
1984.
Comparison of antigens and serological methods in Aspergillus fumigatus antibody detection.
Mykosen
27:43-50[Medline].
|
| 31.
|
Kurup, V. P.,
E. Y. Ting, and J. N. Fink.
1983.
Immunochemical characterization of Aspergillus fumigatus antigens.
Infect. Immun.
41:698-701[Abstract/Free Full Text].
|
| 32.
|
Laufer, P.,
J. N. Fink,
W. T. Bruns,
G. F. Unger,
J. H. Kalbfleisch,
P. A. Greenberger, and R. Patterson.
1984.
Allergic bronchopulmonary aspergillosis in cystic fibrosis.
J. Allergy Clin. Immunol.
73:44-48[Medline].
|
| 33.
|
Leser, C.,
H. F. Kauffman,
C. Virchow, and G. Menz.
1992.
Specific serum immunopatterns in clinical phases of allergic bronchopulmonary aspergillosis.
J. Allergy Clin. Immunol.
90:589-599[Medline].
|
| 34.
|
Mayer, C.,
S. Hemmann,
A. Faith,
K. Blaser, and R. Crameri.
1997.
Cloning, production, characterization and IgE cross-reactivity of different manganese superoxide dismutases in individuals sensitized to Aspergillus fumigatus.
Int. Arch. Allergy Immunol.
113:213-215[Medline].
|
| 35.
|
Monod, M.,
S. Paris,
J. Sarfati,
K. Jaton-Ogay,
P. Ave, and J. P. Latge.
1993.
Virulence of alkaline protease-deficient mutants of Aspergillus fumigatus.
FEMS Microbiol. Lett.
80:39-46.
|
| 36.
|
Moser, M.,
R. Crameri,
E. Brust,
M. Suter, and G. Menz.
1994.
Diagnostic value of recombinant Aspergillus fumigatus allergen I/a for skin testing and serology.
J. Allergy Clin. Immunol.
93:1-11[Medline].
|
| 37.
|
Moser, M.,
R. Crameri,
G. Menz,
T. Schneider,
T. Dudler,
C. Virchow,
M. Gmachl,
K. Blaser, and M. Suter.
1992.
Cloning and expression of recombinant Aspergillus fumigatus allergen I/a (rAsp f I/a) with IgE binding and type I skin test activity.
J. Immunol.
149:454-460[Abstract].
|
| 38.
|
Moser, M.,
G. Menz,
K. Blaser, and R. Crameri.
1994.
Recombinant expression and antigenic properties of a 32-kilodalton extracellular alkaline protease, representing a possible virulence factor from Aspergillus fumigatus.
Infect. Immun.
62:936-946[Abstract/Free Full Text].
|
| 39.
|
Murali, P. S.,
K. Pathial,
R. H. Saff,
M. L. Splaingard,
D. Atluru,
V. P. Kurup, and J. N. Fink.
1994.
Immune responses to Aspergillus fumigatus and Pseudomonas aeruginosa antigens in cystic fibrosis and allergic bronchopulmonary aspergillosis.
Chest
106:513-519[Abstract/Free Full Text].
|
| 40.
|
Nikolaizik, W. H.,
M. Moser,
R. Crameri,
S. Little,
J. O. Warner,
K. Blaser, and M. H. Schoni.
1995.
Identification of allergic bronchopulmonary aspergillosis in cystic fibrosis patients by recombinant Aspergillus fumigatus I/a-specific serology.
Am. J. Respir. Crit. Care Med.
152:634-639[Abstract].
|
| 41.
|
Nikolaizik, W. H.,
R. Crameri,
K. Blaser, and M. H. Schoni.
1996.
Skin test reactivity to recombinant Aspergillus fumigatus allergen I/a in patients with cystic fibrosis.
Int. Arch. Allergy Immunol.
111:403-408[Medline].
|
| 42.
|
Ovejero, M. C.
1993.
Aislamiento y caracterización de antigenos importantes en el immunodiagnóstico de las aspergilosis. Ph.D. thesis.
Universidad de Salamanca, Salamanca, Spain.
|
| 43.
|
Penalver, M. C.,
J. E. O'Connor,
J. P. Martinez, and M. L. Gil.
1996.
Binding of human fibronectin to Aspergillus fumigatus conidia.
Infect. Immun.
64:1146-1153[Abstract].
|
| 44.
|
Piechura, J. E.,
C. J. Huang,
S. H. Cohen,
J. M. Kidd,
V. P. Kurup, and N. J. Calvanico.
1983.
Antigens of Aspergillus fumigatus. II. Electrophoretic and clinical studies.
Immunology
49:657-665[Medline].
|
| 45.
|
Piechura, J. E.,
R. S. Riefel, and L. J. Daft.
1987.
Electrophoretic and serological analyses of cytoplasmic antigens from Aspergillus fumigatus during growth of conidia to mature mycelia.
J. Med. Vet. Mycol.
25:243-254[Medline].
|
| 46.
|
Ramesh, M. V.,
T. Sirakova, and P. E. Kolattukudy.
1994.
Isolation, characterization, and cloning of cDNA and the gene for an elastinolytic serine proteinase from Aspergillus flavus.
Infect. Immun.
62:79-85[Abstract/Free Full Text].
|
| 47.
|
Reed, C.
1978.
Variability of antigenicity of Aspergillus fumigatus.
J. Allergy Clin. Immunol.
61:227-229[Medline].
|
| 48.
|
Rosenberg, M.,
R. Patterson,
R. Mintzer,
B. J. Cooper,
M. Roberts, and K. E. Harris.
1977.
Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis.
Ann. Intern. Med.
86:405-414.
|
| 49.
|
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467[Abstract/Free Full Text].
|
| 50.
|
Sentandreu, M.,
M. V. Elorza,
R. Sentandreu, and W. A. Fonzi.
1998.
Cloning and characterization of PRA1, a gene encoding a novel pH-regulated antigen of Candida albicans.
J. Bacteriol.
180:282-289[Abstract/Free Full Text].
|
| 51.
|
Sheffer, A. L., and V. S. Taggart.
1993.
Expert panel report and guidelines for the diagnosis and management of asthma.
Med. Care
31:MS20-MS28[Medline].
|
| 52.
|
Teshima, R.,
H. Ikebuchi,
J. Sawada,
S. Miyachi,
S. Kitani,
M. Iwama,
M. Irie,
M. Ichinoe, and T. Terao.
1993.
Isolation and characterization of a major allergenic component (gp55) of Aspergillus fumigatus.
J. Allergy Clin. Immunol.
92:698-706[Medline].
|
| 53.
|
Tronchin, G.,
K. Esnault,
G. Renier,
R. Filmon,
D. Chabasse, and J. P. Bouchara.
1997.
Expression and identification of a laminin-binding protein in Aspergillus fumigatus conidia.
Infect. Immun.
65:9-15[Abstract].
|
Infection and Immunity, November 1998, p. 5175-5182, Vol. 66, No. 11
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wang, J.-Y., Cai, Y., Gou, J.-Y., Mao, Y.-B., Xu, Y.-H., Jiang, W.-H., Chen, X.-Y.
(2004). VdNEP, an Elicitor from Verticillium dahliae, Induces Cotton Plant Wilting. Appl. Environ. Microbiol.
70: 4989-4995
[Abstract]
[Full Text]
-
Banerjee, B., Kurup, V. P., Greenberger, P. A., Kelly, K. J., Fink, J. N.
(2002). C-Terminal Cysteine Residues Determine the IgE Binding of Aspergillus fumigatus Allergen Asp f 2. J. Immunol.
169: 5137-5144
[Abstract]
[Full Text]
-
Viudes, A., Perea, S., Lopez-Ribot, J. L.
(2001). Identification of Continuous B-Cell Epitopes on the Protein Moiety of the 58-Kilodalton Cell Wall Mannoprotein of Candida albicans Belonging to a Family of Immunodominant Fungal Antigens. Infect. Immun.
69: 2909-2919
[Abstract]
[Full Text]
-
Cenci, E., Mencacci, A., Bacci, A., Bistoni, F., Kurup, V. P., Romani, L.
(2000). T Cell Vaccination in Mice with Invasive Pulmonary Aspergillosis. J. Immunol.
165: 381-388
[Abstract]
[Full Text]
-
Banerjee, B., Greenberger, P. A., Fink, J. N., Kurup, V. P.
(1999). Conformational and Linear B-Cell Epitopes of Asp f 2, a Major Allergen of Aspergillus fumigatus, Bind Differently to Immunoglobulin E Antibody in the Sera of Allergic Bronchopulmonary Aspergillosis Patients. Infect. Immun.
67: 2284-2291
[Abstract]
[Full Text]